TET2 Antibody

Product Specifications

Background

TET2, a member of the ten-eleven-translocation (TET) family of genes, is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. It is a candidate tumor suppressor gene reported to be mutated in approximately 14% of patients with JAK2V617F-positive myeloproliferative neoplasms (1), and can be mutated in other hematopoietic disorders such as myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia (2) . Analysis of the TET2 and JAK2 mutations in these neoplasms suggests that mutations in TET2 do not represent a predisposition for acquiring mutations in JAK2.

NCBI Gene ID

54790

Swiss Prot

Q6N021

Accession Number

NP_001120680

Host

Rabbit

Reactivity

Human, Mouse

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Cancer, Cell Cycle

Purification

TET2 antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1282 - 3T3 (NIH) Cell Lysate

Concentration

1 mg/mL

Buffer

TET2 Antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

TET2 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year.

Fragment

IgG

Specificity

TET2 antibody is human and mouse reactive. At least two isoforms of TET2 are known to exist; this antibody will detect the larger isoforms. This antibody is predicted to not cross-react with TET1 and TET3.

Symbol

TET2

NCBI Official Name

Tet methylcytosine dioxygenase 2

NCBI Organism

Homo sapiens

Background Reference 01

Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIPL1-PDGFRA correlates. Leukemia 2009; 23:900-4.

Background Reference 02

Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2011; 115:2003-7.